Product Description
Nimodipine is a second-generation 1,4-dihydropyridine calcium channel blocker. It was initially invented for the management of systemic hypertension. FDA approved the use of nimodipine for the first time in 1988. However, its use is restricted mainly in the management of vasospasm following subarachnoid hemorrhage. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30521291/)
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: PDS Biotech
Company Location: FLORHAM PARK NJ 07932
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, United States, Unknown Location
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Aneurysm|Subarachnoid Hemorrhage
Phase 1: Cerebral Hemorrhage|Cerebrovascular Disorders|Memory Disorders|Spasm
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AkNiPro2 | P3 |
Active, not recruiting |
Unknown |
2025-04-17 |
|
| STRIVE-ON | P3 |
Active, not recruiting |
Aneurysm|Subarachnoid Hemorrhage |
2024-12-01 |
|
| SPLASH | P2 |
Active, not recruiting |
Aneurysm|Subarachnoid Hemorrhage |
2023-08-15 |
|
| GTX-104-002 | P1 |
Completed |
Aneurysm|Subarachnoid Hemorrhage |
2022-02-17 |
21% |